Zyla Life Sciences
DelistedCIK 1586105fmd_154NBEB3W33BG7FMJETKSG17YGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Mar 31, 2020, 30 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|
| Total revenues | 1 | – | 2 | 23 | 17 | 26 | 30 |
| Total interest income | – | – | – | 1 | 1 | 1 | – |
| Research and development | 4 | 6 | 22 | 27 | 34 | 15 | 4 |
| Selling, general and administrative | – | – | 17 | 43 | 59 | 70 | 58 |
| Total operating expenses | 6 | 11 | 39 | 75 | 98 | 94 | 88 |
| Operating income | (5) | (11) | (37) | (52) | (81) | (68) | (58) |
| Interest and investment income | – | – | – | – | – | 1 | 1 |
| Other non-operating income (expense) | (0) | (9) | (6) | (6) | (11) | (1) | (29) |
| Income before taxes | (5) | (20) | (43) | (59) | (92) | (69) | (95) |
| Income tax expense | – | 0 | 0 | (1) | (1) | – | – |
| Net income from continuing operations | – | (20) | (43) | (58) | (91) | – | – |
| Net income | – | – | – | (58) | (91) | (69) | (95) |
| Net income to common shareholders | (5) | (20) | (43) | (58) | (91) | (69) | (95) |